AR074474A1 - Inhibidores ns5a de vhc - Google Patents
Inhibidores ns5a de vhcInfo
- Publication number
- AR074474A1 AR074474A1 ARP090104678A ARP090104678A AR074474A1 AR 074474 A1 AR074474 A1 AR 074474A1 AR P090104678 A ARP090104678 A AR P090104678A AR P090104678 A ARP090104678 A AR P090104678A AR 074474 A1 AR074474 A1 AR 074474A1
- Authority
- AR
- Argentina
- Prior art keywords
- group
- heteroaryl
- independently
- heterocyclyl
- cycloalkyl
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Abstract
Compuestos, composiciones farmacéuticas y medicamentos para el tratamiento de hepatitis C. Reivindicación 1: Un compuesto que tiene la fórmula (1) donde A y A' se seleccionan independientemente del grupo formado por una ligadura simple, -(CR2)n-O-(CR2)p-, -(CR2)n-N(RN)-(CR2)p-, -(CR2)n-S(O)k-N(RN)-(CR2)p-, -(CR2)n-C(O)-N(RN)-(CR2)p-, -(CR2)n-N(RN)-C(O)-N(RN)-(CR2)p-, -(CR2)n-C(O)-O-(CR2)p-, -(CR2)n-N(RN)-S(O)k-N(RN)-(CR2)p- y -(CR2)n-N(RN)-C(O)-O-(CR2)p- y un grupo heteroarilo seleccionado del grupo de fórmulas (2), donde X1 es CH2, NH, O ó S; Y1, Y2 y Z1 son cada uno independientemente CH o N; X2 es NH, O ó S; V es -CH2-CH2-, -CH=CH-, -N=CH-, -(CH2)a-N(RN)-(CH2)b- o -(CH2)a-O-(CH2)b-, donde a y b son independientemente 0, 1, 2 ó 3 con la condición de que a y b no son ambos 0; el resto de fórmula (3) incluye opcionalmente 1 ó 2 N como heteroátomos en el residuo fenilo, los carbonos del grupo heteroarilo están cada uno independientemente opcionalmente sustituidos con un sustituyente seleccionado del grupo formado por OH, -CN, -NO2, halógeno, alquilo C1-12, heteroalquilo C1-12, cicloalquilo, heterociclilo, arilo, heteroarilo, aralquilo, alcoxi, alcoxicarbonilo, alcanoilo, carbamoilo, sulfonilo sustituido, sulfonato, sulfonamido y amino, los N, si presentes, del grupo heteroarilo están cada uno independientemente opcionalmente sustituidos con un sustituyente seleccionado del grupo formado por -OH, alquilo C1-12, heteroalquilo C1-12, cicloalquilo, heterociclilo, arilo, heteroarilo, aralquilo, alcoxi, alcoxicarbonilo, alcanoilo, carbamoilo, sulfonilo sustituido, sulfonato y sulfonamido; a y b son independientemente 1, 2 ó 3; c y d son independientemente 1 ó 2; n y p son independientemente 0, 1, 2 ó 3; k es 0, 1 ó 2; cada R se relaciona independientemente del grupo formado por H, -OH, -CN, -NO2, halógeno, alquilo C1-12, heteroalquilo C1-12, cicloalquilo, heterociclilo, arilo, heteroarilo, aralquilo, alcoxi, alcoxicarbonilo, alcanoilo, carbamoilo, sulfonilo sustituido, sulfonato, sulfonamido y amino; cada RN se selecciona independientemente del grupo formado por hidrógeno, -OH, alquilo C1-12, heteroalquilo C1-12, cicloalquilo, heterociclilo, arilo, heteroarilo, aralquilo, alcoxi, alcoxicarbonilo, alcanoilo, carbamoilo, sulfonilo sustituido, sulfonato, y sulfonamido y donde para cada A y A', B puede estar ligado a cualquier lado de A y A', de modo que cuando A o A' es por ejemplo un resto de fórmula (4), entonces A-B-A' puede ser cualquiera de los restos del grupo de fórmulas (5); B es Q o Q-Q, donde Q se selecciona independientemente del grupo formado por un grupo cicloalquilo, grupo cicloalquenilo, heterociclilo, grupo arilo o heteroarilo, con la condición que sólo un Q es un anillo aromático de 6 miembros cuando B es Q-Q y con la condición de que cuando B es Q-Q, entonces cualquier Q que s un policiclilo está conectado al resto de la molécula a través de solo un ciclo del policiclilo; Rc, Rd, Re y Rf se seleccionan cada uno independientemente del grupo formado por H, alquilo C1-8, heteroalquilo C1-8, aralquilo y un anillo de 4 a 8 miembros que puede ser cicloalquilo, heterociclilo, heteroarilo o arilo, donde, cada heteroátomo, si presente, es independientemente N, O ó S, cada uno de Rc, Rd, Re y Rf puede estar opcionalmente sustituido por alquilo C1-8, heteroalquilo C1-8, aralquilo o un anillo de 4 a 8 miembros que puede ser cicloalquilo, heterociclilo, heteroarilo o arilo y donde cada heteroátomo, si presente, es independientemente N, O ó S, Rc y Rd se unen opcionalmente para formar un heterociclo de 4 a 8 miembros fusionado opcionalmente con otro anillo heterocíclico o heteroarilo de 3 a 6 miembros, y Re y Rf se unen opcionalmente para formar un heterociclo de 4 a 8 miembros fusionado opcionalmente con otro anillo heterociclilo o heteroarilo de 3 a 6 miembros; Y e Y' son cada uno independientemente C o N; y Z y Z' se seleccionan independientemente del grupo formado por H, alquilo C1-8, heteroalquilo C1-8, cicloalquilo, heterociclilo, arilo, heteroarilo, aralquilo, 1-3 aminoácidos, -[U-(CR42)t-NR5-(CR42)t]u-U-(CR42)t-NR7-(CR42)t-R8, -U-(CR42)t-R8 y -[U-(CR42)t-NR5-(CR42)t]u-U-(CR42)t-O-(CR42)t-R8, donde U se selecciona del grupo formado por -C(O)-, -C(S)- y -S(O)2-, cada R4, R5 y R7 se selecciona independientemente del grupo formado por H, alquilo C1-8, heteroalquilo C1-8, cicloalquilo, heterociclilo, arilo, heteroarilo y aralquilo; R8 se selecciona independientemente del grupo formado por H, alquilo C1-8, heteroalquilo C1-8, cicloalquilo, heterociclilo, arilo, heteroarilo, aralquilo, -C(O)-R81, -C(S)-R81-C(O)-O-R81, -C(O)-N-R812, -S(O)2-R81 y -S(O)2-N-R812, donde cada R81 se selecciona independientemente del grupo formado por H, alquilo C1-8, heteroalquilo C1-8, cicloalquilo, heterociclilo, arilo, heteroarilo y aralquilo, opcionalmente, R7 y R8 forman conjuntamente un anillo de 4-7 miembros, cada t es independientemente 0, 1, 2, 3 ó 4, y u es 0, 1 ó 2.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11972308P | 2008-12-03 | 2008-12-03 | |
US17359009P | 2009-04-28 | 2009-04-28 | |
US18295209P | 2009-06-01 | 2009-06-01 | |
PCT/US2009/066467 WO2010065681A1 (en) | 2008-12-03 | 2009-12-02 | Inhibitors of hcv ns5a |
Publications (1)
Publication Number | Publication Date |
---|---|
AR074474A1 true AR074474A1 (es) | 2011-01-19 |
Family
ID=42233598
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP090104677A AR080264A1 (es) | 2008-12-03 | 2009-12-03 | Inhibidores ns5a de vhc |
ARP090104678A AR074474A1 (es) | 2008-12-03 | 2009-12-03 | Inhibidores ns5a de vhc |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP090104677A AR080264A1 (es) | 2008-12-03 | 2009-12-03 | Inhibidores ns5a de vhc |
Country Status (20)
Country | Link |
---|---|
US (3) | US9120779B2 (es) |
EP (3) | EP2373167A4 (es) |
JP (2) | JP2012510525A (es) |
KR (1) | KR20110098779A (es) |
CN (2) | CN102300461B (es) |
AR (2) | AR080264A1 (es) |
AU (2) | AU2009322387A1 (es) |
BR (1) | BRPI0922364A2 (es) |
CA (2) | CA2745119A1 (es) |
CL (1) | CL2011001332A1 (es) |
CO (1) | CO6390076A2 (es) |
EA (1) | EA201190007A1 (es) |
IL (2) | IL213279A0 (es) |
MX (1) | MX2011005896A (es) |
NZ (2) | NZ593806A (es) |
PE (1) | PE20120207A1 (es) |
SG (2) | SG171891A1 (es) |
TW (2) | TWI472526B (es) |
WO (2) | WO2010065668A1 (es) |
ZA (1) | ZA201104911B (es) |
Families Citing this family (156)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8563573B2 (en) | 2007-11-02 | 2013-10-22 | Vertex Pharmaceuticals Incorporated | Azaindole derivatives as CFTR modulators |
AU2009322393B2 (en) * | 2008-12-03 | 2017-02-02 | Presidio Pharmaceuticals, Inc. | Inhibitors of HCV NS5A |
EP2367823A1 (en) | 2008-12-23 | 2011-09-28 | Abbott Laboratories | Anti-viral compounds |
ES2567047T3 (es) | 2008-12-23 | 2016-04-19 | Abbvie Inc. | Derivados de pirimidina anti-virales |
US8314135B2 (en) | 2009-02-09 | 2012-11-20 | Enanta Pharmaceuticals, Inc. | Linked dibenzimidazole antivirals |
US8394968B2 (en) | 2009-02-17 | 2013-03-12 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
TWI438200B (zh) * | 2009-02-17 | 2014-05-21 | 必治妥美雅史谷比公司 | C型肝炎病毒抑制劑 |
US8420686B2 (en) | 2009-02-17 | 2013-04-16 | Enanta Pharmaceuticals, Inc. | Linked diimidazole antivirals |
US8188132B2 (en) | 2009-02-17 | 2012-05-29 | Enanta Pharmaceuticals, Inc. | Linked dibenzimidazole derivatives |
US8637561B2 (en) * | 2009-02-17 | 2014-01-28 | Enanta Pharmaceuticals, Inc. | Linked diimidazole derivatives |
US8242156B2 (en) | 2009-02-17 | 2012-08-14 | Enanta Pharmaceuticals, Inc. | Linked dibenzimidazole derivatives |
US9765087B2 (en) | 2009-02-27 | 2017-09-19 | Enanta Pharmaceuticals, Inc. | Benzimidazole derivatives |
US8426458B2 (en) * | 2009-02-27 | 2013-04-23 | Enanta Pharmaceuticals, Inc. | Hepatitis C Virus inhibitors |
US8673954B2 (en) | 2009-02-27 | 2014-03-18 | Enanta Pharmaceuticals, Inc. | Benzimidazole derivatives |
US8101643B2 (en) | 2009-02-27 | 2012-01-24 | Enanta Pharmaceuticals, Inc. | Benzimidazole derivatives |
SG174146A1 (en) * | 2009-02-27 | 2011-10-28 | Enanta Pharm Inc | Hepatitis c virus inhibitors |
AU2013204195B2 (en) * | 2009-02-27 | 2016-09-22 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
US8507522B2 (en) | 2009-03-06 | 2013-08-13 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
WO2010111673A1 (en) | 2009-03-27 | 2010-09-30 | Presidio Pharmaceuticals, Inc. | Substituted bicyclic hcv inhibitors |
US8796466B2 (en) * | 2009-03-30 | 2014-08-05 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
TWI476190B (zh) * | 2009-03-30 | 2015-03-11 | 必治妥美雅史谷比公司 | C型肝炎病毒抑制劑 |
TW201038559A (en) | 2009-04-09 | 2010-11-01 | Bristol Myers Squibb Co | Hepatitis C virus inhibitors |
US8143414B2 (en) | 2009-04-13 | 2012-03-27 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
CA2758484A1 (en) | 2009-04-15 | 2010-10-21 | David A. Degoey | Anti-viral compounds |
JP2012526834A (ja) | 2009-05-12 | 2012-11-01 | シェーリング コーポレイション | ウイルス疾患治療に有用な縮合型三環式アリール化合物 |
MX360800B (es) | 2009-05-13 | 2018-11-16 | Gilead Pharmasset Llc Star | Compuestos antivirales. |
AU2010253791A1 (en) | 2009-05-29 | 2011-11-24 | Merck Sharp & Dohme Corp. | Antiviral compounds composed of three linked Aryl moieties to treat diseases such as Hepatitis C |
US8211928B2 (en) | 2009-05-29 | 2012-07-03 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
EP2435421A1 (en) * | 2009-05-29 | 2012-04-04 | Schering Corporation | Antiviral compounds composed of three aligned aryl moieties to treat diseases such as hepatitis c |
US8138215B2 (en) | 2009-05-29 | 2012-03-20 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
CN103819459B (zh) * | 2009-06-11 | 2017-05-17 | 艾伯维巴哈马有限公司 | 抗病毒化合物 |
US9394279B2 (en) | 2009-06-11 | 2016-07-19 | Abbvie Inc. | Anti-viral compounds |
US8716454B2 (en) | 2009-06-11 | 2014-05-06 | Abbvie Inc. | Solid compositions |
US8937150B2 (en) | 2009-06-11 | 2015-01-20 | Abbvie Inc. | Anti-viral compounds |
US8221737B2 (en) | 2009-06-16 | 2012-07-17 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
US8609648B2 (en) | 2009-07-02 | 2013-12-17 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
WO2011009084A2 (en) | 2009-07-16 | 2011-01-20 | Vertex Pharmaceuticals Incorporated | Benzimidazole analogues for the treatment or prevention of flavivirus infections |
TW201116525A (en) | 2009-07-21 | 2011-05-16 | Gilead Sciences Inc | Inhibitors of flaviviridae viruses |
WO2011015657A1 (en) | 2009-08-07 | 2011-02-10 | Tibotec Pharmaceuticals | Phenyl ethynyl derivatives as hepatitis c virus inhibitors |
RU2540897C2 (ru) * | 2009-08-07 | 2015-02-10 | Тиботек Фармасьютикалз | Производные бис-бензимидазола в качестве ингибиторов вируса гепатита с |
CN102482260A (zh) | 2009-09-03 | 2012-05-30 | 泰博特克药品公司 | 双-苯并咪唑衍生物 |
US8344155B2 (en) | 2009-09-04 | 2013-01-01 | Glaxosmith Kline Llc | Chemical compounds |
JP5774008B2 (ja) | 2009-09-09 | 2015-09-02 | ギリアード サイエンシーズ, インコーポレイテッド | Flaviviridaeウイルスの阻害剤 |
US8822700B2 (en) | 2009-09-11 | 2014-09-02 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
US8759332B2 (en) | 2009-09-11 | 2014-06-24 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
EP2475254A4 (en) * | 2009-09-11 | 2013-05-22 | Enanta Pharm Inc | HEPATITIS C-VIRUS HEMMER |
US8927709B2 (en) | 2009-09-11 | 2015-01-06 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
US8815928B2 (en) | 2009-09-11 | 2014-08-26 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
EP2475256A4 (en) | 2009-09-11 | 2013-06-05 | Enanta Pharm Inc | HEPATITIS C-VIRUS HEMMER |
US8703938B2 (en) | 2009-09-11 | 2014-04-22 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
UA108211C2 (uk) * | 2009-11-04 | 2015-04-10 | Янссен Рід Айрленд | Бензімідазолімідазольні похідні |
US20110269956A1 (en) | 2009-11-11 | 2011-11-03 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
US20110274648A1 (en) * | 2009-11-11 | 2011-11-10 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
US20110281910A1 (en) * | 2009-11-12 | 2011-11-17 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
EP2512480A4 (en) | 2009-12-14 | 2013-05-15 | Enanta Pharm Inc | HEPATITIS C-VIRUS HEMMER |
US8377980B2 (en) | 2009-12-16 | 2013-02-19 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
CN104530079B (zh) * | 2009-12-18 | 2017-10-20 | 北京凯因科技股份有限公司 | C型肝炎病毒复制的新型抑制剂 |
JP2013514982A (ja) | 2009-12-18 | 2013-05-02 | イデニク プハルマセウティカルス,インコーポレイテッド | 5,5−縮合アリーレン又はヘテロアリーレンc型肝炎ウイルス阻害剤 |
US20130156731A1 (en) | 2009-12-22 | 2013-06-20 | Kevin X. Chen | Fused tricyclic compounds and methods of use thereof for the treatment of viral diseas |
CN102883718A (zh) * | 2009-12-24 | 2013-01-16 | 顶点制药公司 | 用于治疗或预防黄病毒感染的类似物 |
US8362020B2 (en) | 2009-12-30 | 2013-01-29 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
CA2785567C (en) | 2010-01-15 | 2018-03-27 | Gilead Sciences, Inc. | Inhibitors of flaviviridae viruses |
KR20120123678A (ko) | 2010-01-15 | 2012-11-09 | 길리애드 사이언시즈, 인코포레이티드 | 플라비비리다에 바이러스의 억제제 |
US8785487B2 (en) | 2010-01-25 | 2014-07-22 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
US8933110B2 (en) | 2010-01-25 | 2015-01-13 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
US8623814B2 (en) | 2010-02-23 | 2014-01-07 | Enanta Pharmaceuticals, Inc. | Antiviral agents |
US8178531B2 (en) | 2010-02-23 | 2012-05-15 | Enanta Pharmaceuticals, Inc. | Antiviral agents |
US9060971B2 (en) | 2010-03-04 | 2015-06-23 | Enanta Pharmaceuticals, Inc. | Combination pharmaceutical agents as inhibitors of HCV replication |
SG183526A1 (en) | 2010-03-09 | 2012-09-27 | Merck Sharp & Dohme | Fused tricyclic silyl compounds and methods of use thereof for the treatment of viral diseases |
EP2550268A1 (en) * | 2010-03-24 | 2013-01-30 | Vertex Pharmaceuticals Incorporated | Analogues for the treatment or prevention of flavivirus infections |
JP2013522375A (ja) | 2010-03-24 | 2013-06-13 | バーテックス ファーマシューティカルズ インコーポレイテッド | フラビウイルス感染を処置または予防するためのアナログ |
US8802868B2 (en) | 2010-03-25 | 2014-08-12 | Vertex Pharmaceuticals Incorporated | Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide |
WO2011127350A1 (en) | 2010-04-09 | 2011-10-13 | Enanta Pharmaceuticals, Inc. | Hepatitis c virus inhibitors |
JP2013525371A (ja) | 2010-04-22 | 2013-06-20 | バーテックス ファーマシューティカルズ インコーポレイテッド | シクロアルキルカルボキサミド−インドール化合物の製造方法 |
EP2575475A4 (en) * | 2010-05-28 | 2013-11-27 | Presidio Pharmaceuticals Inc | HCV NS5A INHIBITORS |
EP2575819A4 (en) | 2010-06-04 | 2013-11-27 | Enanta Pharm Inc | INHIBITORS OF HEPATITIS C VIRUS |
TW201201801A (en) * | 2010-06-09 | 2012-01-16 | Presidio Pharmaceuticals Inc | Inhibitors of HCV NS5A protein |
NZ605440A (en) | 2010-06-10 | 2014-05-30 | Abbvie Bahamas Ltd | Solid compositions comprising an hcv inhibitor |
WO2012006055A2 (en) | 2010-06-28 | 2012-01-12 | Vertex Pharmaceuticals Incorporated | Compounds and methods for the treatment or prevention of flavivirus infections |
WO2012006060A1 (en) | 2010-06-28 | 2012-01-12 | Vertex Pharmaceuticals Incorporated | Compounds and methods for the treatment or prevention of flavivirus infections |
US20140377223A1 (en) | 2010-07-26 | 2014-12-25 | Joseph A. Kozlowski | Substituted biphenylene compounds and methods of use thereof for the treatment of viral diseases |
AU2011284857B2 (en) | 2010-07-26 | 2014-07-24 | Janssen Sciences Ireland Uc | Hetero-bicyclic derivatives as HCV inhibitors |
CN103153986B (zh) * | 2010-08-04 | 2014-11-05 | 百时美施贵宝公司 | 丙型肝炎病毒抑制剂 |
US8697704B2 (en) | 2010-08-12 | 2014-04-15 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
EP2606041A2 (en) | 2010-08-17 | 2013-06-26 | Vertex Pharmaceuticals Incorporated | Compounds and methods for the treatment or prevention of flaviviridae viral infections |
BR112013004520A2 (pt) | 2010-08-26 | 2016-06-07 | Univ Emory | inibidores potentes e seletivos do virus da hepatite c |
WO2012040389A2 (en) * | 2010-09-22 | 2012-03-29 | Presidio Pharmaceuticals, Inc. | Substituted bicyclic hcv inhibitors |
CN103249730A (zh) * | 2010-09-24 | 2013-08-14 | 百时美施贵宝公司 | 丙型肝炎病毒抑制剂 |
US9254292B2 (en) | 2010-09-29 | 2016-02-09 | Merck Sharp & Dohme Corp. | Fused tetracycle derivatives and methods of use thereof for the treatment of viral diseases |
CN103459399A (zh) * | 2010-09-29 | 2013-12-18 | 默沙东公司 | 用于治疗丙型肝炎病毒感染的四环吲哚衍生物 |
WO2012050918A2 (en) | 2010-09-29 | 2012-04-19 | Presidio Pharmaceutical, Inc. | Tricyclic fused ring inhibitors of hepatitis c |
BR112013007696A2 (pt) * | 2010-09-29 | 2019-09-24 | Merck Sharp & Dohme | composto, composição farmacêutica, usos do referido composto e da referida composição |
CA2938547A1 (en) * | 2010-10-13 | 2012-04-19 | Abbvie Bahamas Ltd. | Anti-viral compounds |
AU2014203655B2 (en) * | 2010-10-13 | 2016-07-07 | Abbvie Ireland Unlimited Company | Anti-viral compounds |
CN103269586B (zh) | 2010-10-26 | 2015-07-15 | 普雷西迪奥制药公司 | 丙型肝炎病毒抑制剂 |
CA2814534A1 (en) | 2010-11-04 | 2012-05-10 | Theravance, Inc. | Novel inhibitors of hepatitis c virus |
PT2640719T (pt) | 2010-11-17 | 2017-07-25 | Gilead Pharmasset Llc | Compostos antivirais |
RU2452735C1 (ru) | 2010-11-30 | 2012-06-10 | Александр Васильевич Иващенко | Замещенные азолы, противовирусный активный компонент, фармацевтическая композиция, способ получения и применения |
EP2651925A4 (en) * | 2010-12-15 | 2014-06-18 | Abbvie Inc | ANTI-VIRAL COMPOUNDS |
WO2012083048A2 (en) * | 2010-12-15 | 2012-06-21 | Abbott Laboratories | Anti-viral compounds |
WO2012083043A1 (en) * | 2010-12-15 | 2012-06-21 | Abbott Laboratories | Anti-viral compounds |
EP2651928A4 (en) * | 2010-12-15 | 2014-06-18 | Abbvie Inc | ANTI-VIRAL COMPOUNDS |
JP5906253B2 (ja) * | 2010-12-16 | 2016-04-20 | アッヴィ・インコーポレイテッド | 抗ウイルス性化合物 |
WO2012087976A2 (en) * | 2010-12-21 | 2012-06-28 | Intermune, Inc. | Novel inhibitors of hepatitis c virus replication |
WO2012091115A1 (ja) * | 2010-12-29 | 2012-07-05 | キッセイ薬品工業株式会社 | アセチレン誘導体及びその医薬用途 |
US8552047B2 (en) | 2011-02-07 | 2013-10-08 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US9546160B2 (en) | 2011-05-12 | 2017-01-17 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US10201584B1 (en) | 2011-05-17 | 2019-02-12 | Abbvie Inc. | Compositions and methods for treating HCV |
JP5669984B2 (ja) | 2011-05-18 | 2015-02-18 | エナンタ ファーマシューティカルズ インコーポレイテッド | 5−アザスピロ[2.4]ヘプタン−6−カルボン酸およびその誘導体の製造方法 |
JP5987056B2 (ja) | 2011-07-13 | 2016-09-06 | ギリアード サイエンシーズ, インコーポレイテッド | Flaviviridaeウイルスのインヒビターとして有用なチオフェン−2−カルボン酸誘導体 |
WO2013016499A1 (en) | 2011-07-26 | 2013-01-31 | Vertex Pharmaceuticals Incorporated | Methods for preparation of thiophene compounds |
TW201317223A (zh) | 2011-07-26 | 2013-05-01 | Vertex Pharma | 噻吩化合物 |
WO2013030750A1 (en) | 2011-09-01 | 2013-03-07 | Lupin Limited | Antiviral compounds |
WO2013039876A1 (en) | 2011-09-14 | 2013-03-21 | Merck Sharp & Dohme Corp. | Silyl-containing heterocyclic compounds and methods of use thereof for the treatment of viral diseases |
LT2709613T (lt) | 2011-09-16 | 2018-02-12 | Gilead Pharmasset Llc | Žmogaus hepatito viruso (hcv) gydymo būdai |
UA119437C2 (uk) | 2011-11-16 | 2019-06-25 | Гайлід Фармассет Елелсі | Противірусні сполуки |
ES2564906T3 (es) * | 2011-12-16 | 2016-03-29 | F. Hoffmann-La Roche Ag | Inhibidores de NS5A del VHC |
CA2858646A1 (en) | 2011-12-28 | 2013-07-04 | Janssen R&D Ireland | Quinazolinone derivatives as hcv inhibitors |
RU2621734C1 (ru) * | 2011-12-28 | 2017-06-07 | Янссен Сайенсиз Айрлэнд Юси | Гетеробициклические производные в качестве ингибиторов hcv |
US9034832B2 (en) | 2011-12-29 | 2015-05-19 | Abbvie Inc. | Solid compositions |
US9326973B2 (en) | 2012-01-13 | 2016-05-03 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
NZ628515A (en) | 2012-02-10 | 2016-06-24 | Lupin Ltd | Antiviral compounds with a dibenzooxaheterocycle moiety |
WO2013142157A1 (en) | 2012-03-22 | 2013-09-26 | Alios Biopharma, Inc. | Pharmaceutical combinations comprising a thionucleotide analog |
PL2840080T3 (pl) | 2012-04-17 | 2018-06-29 | Fujifilm Corporation | Zawierający azot związek heterocykliczny lub jego sól |
US20130309196A1 (en) | 2012-05-16 | 2013-11-21 | Gilead Sciences, Inc. | Antiviral compounds |
TWI610916B (zh) | 2012-08-03 | 2018-01-11 | 廣東東陽光藥業有限公司 | 作爲丙型肝炎抑制劑的橋環化合物及其在藥物中的應用 |
US8927741B2 (en) | 2012-08-17 | 2015-01-06 | Gilead Sciences, Inc. | Synthesis of an antiviral compound |
US8759544B2 (en) | 2012-08-17 | 2014-06-24 | Gilead Sciences, Inc. | Synthesis of an antiviral compound |
US8841340B2 (en) | 2012-08-17 | 2014-09-23 | Gilead Sciences, Inc. | Solid forms of an antiviral compound |
US9802949B2 (en) | 2012-11-29 | 2017-10-31 | Sunshine Lake Pharma Co., Ltd. | Fused ring compounds as hepatitis C virus inhibitors, pharmaceutical compositions and uses thereof |
TWI585082B (zh) | 2012-11-29 | 2017-06-01 | 廣東東陽光藥業有限公司 | 作爲丙型肝炎抑制劑的螺環化合物、藥物組合物及它們的用途 |
CN103880823B (zh) * | 2012-12-21 | 2017-12-05 | 广东东阳光药业有限公司 | 作为丙型肝炎抑制剂的螺环化合物及其在药物中的应用 |
PE20151778A1 (es) | 2013-01-31 | 2015-12-16 | Gilead Pharmasset Llc | Formulacion combinada de dos compuestos antivirales |
RU2507201C1 (ru) | 2013-02-07 | 2014-02-20 | Александр Васильевич Иващенко | Алкил [(s)-1-((s)-2-{5-[4-(4-{2-[(s)-1-((s)-2-метоксикарбониламино-3-метил-бутирил)-пирролидин-2-ил]-3н-имидазол-4-ил}-бута-1,3-диинил)-фенил]-1н-имидазол-2-ил}-пирролидин-1-карбонил)-2-метил-пропил]-карбамат нафталин-1,5-дисульфонат, фармацевтическая композиция, лекарственное средство, способ лечения вирусных заболеваний |
WO2014134251A1 (en) | 2013-02-28 | 2014-09-04 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions |
US11484534B2 (en) | 2013-03-14 | 2022-11-01 | Abbvie Inc. | Methods for treating HCV |
US9717712B2 (en) | 2013-07-02 | 2017-08-01 | Bristol-Myers Squibb Company | Combinations comprising tricyclohexadecahexaene derivatives for use in the treatment of hepatitis C virus |
US20150023913A1 (en) | 2013-07-02 | 2015-01-22 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
CN105530933B (zh) | 2013-07-17 | 2018-12-11 | 百时美施贵宝公司 | 用于治疗hcv的包含联苯衍生物的组合产品 |
SI3038601T1 (sl) | 2013-08-27 | 2020-07-31 | Gilead Pharmasset Llc | Formulacija kombinacije dveh protivirusnih spojin |
EP3063140A4 (en) | 2013-10-30 | 2017-11-08 | Merck Sharp & Dohme Corp. | Pseudopolymorphs of an hcv ns5a inhibitor and uses thereof |
CN103664581B (zh) * | 2013-12-20 | 2016-07-06 | 中节能万润股份有限公司 | 一种反,反-4,4’-二环己基二甲酸的制备方法 |
WO2015089810A1 (en) | 2013-12-20 | 2015-06-25 | Merck Sharp & Dohme Corp. | Fused tetracyclic heterocyclic compounds and methods of use thereof for the treatment of viral diseases |
EP3089757A1 (en) | 2014-01-03 | 2016-11-09 | AbbVie Inc. | Solid antiviral dosage forms |
WO2015110048A1 (en) | 2014-01-23 | 2015-07-30 | Sunshine Lake Pharma Co., Ltd. | Bridged ring compounds as hepatitis c virus inhibitors, pharmaceutical compositions and uses thereof |
EP4223294A1 (en) | 2014-04-15 | 2023-08-09 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases |
CN105175408B (zh) * | 2014-06-04 | 2018-07-17 | 中国人民解放军第二军医大学 | 苯并噻唑类化合物及其作为药物的用途 |
TWI721947B (zh) | 2014-06-11 | 2021-03-21 | 美商基利法瑪席特有限責任公司 | 抗病毒化合物的固態形式 |
GB201506660D0 (en) | 2015-04-20 | 2015-06-03 | Cellcentric Ltd | Pharmaceutical compounds |
GB201506658D0 (en) | 2015-04-20 | 2015-06-03 | Cellcentric Ltd | Pharmaceutical compounds |
WO2017023631A1 (en) | 2015-08-06 | 2017-02-09 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
CN106279117A (zh) * | 2016-08-16 | 2017-01-04 | 上海同昌生物医药科技有限公司 | 一种雷迪帕韦中间体的合成方法及其产品 |
CN108727345B (zh) * | 2017-04-25 | 2023-06-27 | 广东东阳光药业有限公司 | 一种咪唑环中间体的制备方法 |
EP3891508A1 (en) | 2018-12-04 | 2021-10-13 | Bristol-Myers Squibb Company | Methods of analysis using in-sample calibration curve by multiple isotopologue reaction monitoring |
CA3182131A1 (en) | 2020-05-22 | 2021-11-25 | Aligos Therapeutics, Inc. | Methods and compositions for targeting pd-l1 |
IL309232A (en) | 2021-06-14 | 2024-02-01 | Scorpion Therapeutics Inc | History of urea which can be used to treat cancer |
Family Cites Families (58)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT1244507B (it) * | 1991-04-11 | 1994-07-15 | Sigma Tau Ind Farmaceuti | Derivati dell'acido piroglutammico quali attivatori dei processi di apprendimento e della memoria e composizioni farmaceutiche comprendenti tali composti |
DE4234295A1 (de) * | 1992-10-12 | 1994-04-14 | Thomae Gmbh Dr K | Carbonsäurederivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
US5807876A (en) | 1996-04-23 | 1998-09-15 | Vertex Pharmaceuticals Incorporated | Inhibitors of IMPDH enzyme |
US6054472A (en) | 1996-04-23 | 2000-04-25 | Vertex Pharmaceuticals, Incorporated | Inhibitors of IMPDH enzyme |
JPH09227417A (ja) * | 1996-02-26 | 1997-09-02 | Dainippon Ink & Chem Inc | アルケニルトラン誘導体とその製造方法 |
IL126674A (en) | 1996-04-23 | 2005-08-31 | Vertex Pharma | Use of cyclic and heterocyclic compounds for preparing pharmaceutical compositions inhibiting impdh activity, pharmaceutical compositions containing the same and novel thiazole and oxazole urea derivatives |
JP3865084B2 (ja) * | 1996-07-04 | 2007-01-10 | 大日本インキ化学工業株式会社 | ジアルケニルトラン誘導体 |
HU227742B1 (en) | 1996-10-18 | 2012-02-28 | Vertex Pharma | Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease |
GB9623908D0 (en) | 1996-11-18 | 1997-01-08 | Hoffmann La Roche | Amino acid derivatives |
JP4327910B2 (ja) | 1997-03-14 | 2009-09-09 | バーテックス ファーマシューティカルズ インコーポレイテッド | Impdh酵素のインヒビター |
US6010848A (en) | 1997-07-02 | 2000-01-04 | Smithkline Beecham Corporation | Screening methods using an atpase protein from hepatitis C virus |
JP4452401B2 (ja) | 1997-08-11 | 2010-04-21 | ベーリンガー インゲルハイム (カナダ) リミテッド | C型肝炎ウイルス阻害ペプチドアナログ |
ES2244204T3 (es) | 1998-07-27 | 2005-12-01 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | Derivados de dicetoacidos como inhibidores de polimerasas. |
US6323180B1 (en) | 1998-08-10 | 2001-11-27 | Boehringer Ingelheim (Canada) Ltd | Hepatitis C inhibitor tri-peptides |
JP2002523371A (ja) | 1998-08-21 | 2002-07-30 | バイロファーマ・インコーポレイテッド | ウイルス感染および関連疾患を治療または予防するための化合物、組成物および方法 |
JP2002524423A (ja) | 1998-09-04 | 2002-08-06 | バイロファーマ・インコーポレイテッド | ウイルス感染および関連疾患の治療および予防方法 |
WO2000018231A1 (en) | 1998-09-25 | 2000-04-06 | Viropharma Incorporated | Methods for treating or preventing viral infections and associated diseases |
JP4184610B2 (ja) | 1999-03-19 | 2008-11-19 | バーテックス ファーマシューティカルズ インコーポレイテッド | Impdh酵素のインヒビター |
AU2935200A (en) | 1999-04-30 | 2000-11-17 | Pfizer Products Inc. | Compounds for the treatment of obesity |
EP1225899A2 (en) | 1999-11-04 | 2002-07-31 | Virochem Pharma Inc. | Method for the treatment or prevention of flaviviridae viral infection using nucleoside analogues |
JP2001294541A (ja) * | 2000-04-14 | 2001-10-23 | Dainippon Ink & Chem Inc | トラン誘導体の製造方法 |
US20040034041A1 (en) | 2000-05-10 | 2004-02-19 | Dashyant Dhanak | Novel anti-infectives |
US6448281B1 (en) | 2000-07-06 | 2002-09-10 | Boehringer Ingelheim (Canada) Ltd. | Viral polymerase inhibitors |
SV2003000617A (es) | 2000-08-31 | 2003-01-13 | Lilly Co Eli | Inhibidores de la proteasa peptidomimetica ref. x-14912m |
EP1256628A3 (en) | 2001-05-10 | 2003-03-19 | Agouron Pharmaceuticals, Inc. | Hepatitis c virus (hcv) ns5b rna polymerase and mutants thereof |
CA2449999C (en) | 2001-06-11 | 2012-07-31 | Shire Biochem Inc. | Compounds and methods for the treatment or prevention of flavivirus infections |
CN101624391A (zh) | 2001-06-11 | 2010-01-13 | 病毒化学医药公司 | 用作黄病毒感染抗病毒剂的噻吩衍生物 |
AR035543A1 (es) | 2001-06-26 | 2004-06-16 | Japan Tobacco Inc | Agente terapeutico para la hepatitis c que comprende un compuesto de anillo condensado, compuesto de anillo condensado, composicion farmaceutica que lo comprende, compuestos de benzimidazol, tiazol y bifenilo utiles como intermediarios para producir dichos compuestos, uso del compuesto de anillo con |
WO2003007959A1 (en) | 2001-07-16 | 2003-01-30 | Fujisawa Pharmaceutical Co., Ltd. | Quinoxaline derivatives which have parp inhibitory action |
US6841566B2 (en) | 2001-07-20 | 2005-01-11 | Boehringer Ingelheim, Ltd. | Viral polymerase inhibitors |
EP2335700A1 (en) | 2001-07-25 | 2011-06-22 | Boehringer Ingelheim (Canada) Ltd. | Hepatitis C virus polymerase inhibitors with a heterobicylic structure |
WO2003037893A1 (en) | 2001-11-02 | 2003-05-08 | Glaxo Group Limited | Acyl dihydro pyrrole derivatives as hcv inhibitors |
WO2003037895A1 (en) | 2001-11-02 | 2003-05-08 | Glaxo Group Limited | 4-(6-membered)-heteroaryl acyl pyrrolidine derivatives as hcv inhibitors |
EP1440070A1 (en) | 2001-11-02 | 2004-07-28 | Glaxo Group Limited | 4-(5-membered)-heteroaryl acyl pyrrolidine derivatives as hcv inhibitors |
EP1551811A1 (en) | 2002-10-17 | 2005-07-13 | Amgen Inc. | Benzimidazole derivatives and their use as vanilloid receptor ligands |
MXPA05005379A (es) * | 2002-11-19 | 2006-02-17 | Achillion Pharmaceuticals Inc | Tioureas de arilo sustituidas y compuestos relacionados; inhibidores de duplicacion viral. |
EP1572112A4 (en) | 2002-11-22 | 2006-12-06 | Bristol Myers Squibb Co | 3- (PYRIDINYL-PIPERAZINE-1-YL) -PHENYLETHYL AMIDES AS POTASIC CHANNEL OPENING AGENTS |
KR101164070B1 (ko) * | 2003-05-09 | 2012-07-12 | 베링거 인겔하임 인터내셔날 게엠베하 | C형 간염 바이러스 ns5b 폴리머라제 억제제 결합 포켓 |
CA2531619A1 (en) | 2003-07-16 | 2005-01-27 | Neurogen Corporation | Biaryl piperazinyl-pyridine analogues |
ES2336009T3 (es) | 2004-01-30 | 2010-04-07 | Medivir Ab | Inhibidores de la ns-3 serina proteasa del vhc. |
CN101027051A (zh) * | 2004-07-14 | 2007-08-29 | Ptc医疗公司 | 治疗丙型肝炎的方法 |
BRPI0511834A (pt) | 2004-07-14 | 2008-01-08 | Ptc Therapeutics Inc | métodos por tratar hepatite c |
US8143288B2 (en) | 2005-06-06 | 2012-03-27 | Bristol-Myers Squibb Company | Inhibitors of HCV replication |
TWI375670B (en) * | 2005-07-29 | 2012-11-01 | Tibotec Pharm Ltd | Macrocylic inhibitors of hepatitis c virus |
TW200813015A (en) | 2006-03-15 | 2008-03-16 | Mitsubishi Pharma Corp | 2-(cyclic amino)-pyrimidone derivatives |
US7759495B2 (en) * | 2006-08-11 | 2010-07-20 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US8329159B2 (en) | 2006-08-11 | 2012-12-11 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US7659270B2 (en) * | 2006-08-11 | 2010-02-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
SG176488A1 (en) * | 2006-11-15 | 2011-12-29 | Virochem Pharma Inc | Thiophene analogues for the treatment or prevention of flavivirus infections |
WO2008073461A2 (en) * | 2006-12-11 | 2008-06-19 | Wyeth | Ion channel modulators |
US7723343B2 (en) * | 2007-03-30 | 2010-05-25 | King Pharmaceuticals Research And Development, Inc. | Adenosine A2A receptor antagonists |
CN101280196B (zh) * | 2008-06-03 | 2011-01-26 | 西安近代化学研究所 | 四环液晶化合物 |
US7906655B2 (en) * | 2008-08-07 | 2011-03-15 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US8383094B2 (en) | 2008-10-01 | 2013-02-26 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
AU2009322393B2 (en) * | 2008-12-03 | 2017-02-02 | Presidio Pharmaceuticals, Inc. | Inhibitors of HCV NS5A |
WO2010091413A1 (en) | 2009-02-09 | 2010-08-12 | Enanta Pharmaceuticals, Inc. | Linked dibenzimidazole derivatives |
SG174146A1 (en) | 2009-02-27 | 2011-10-28 | Enanta Pharm Inc | Hepatitis c virus inhibitors |
MX360800B (es) * | 2009-05-13 | 2018-11-16 | Gilead Pharmasset Llc Star | Compuestos antivirales. |
-
2009
- 2009-12-02 BR BRPI0922364A patent/BRPI0922364A2/pt not_active IP Right Cessation
- 2009-12-02 KR KR1020117015471A patent/KR20110098779A/ko not_active Application Discontinuation
- 2009-12-02 PE PE2011001155A patent/PE20120207A1/es not_active Application Discontinuation
- 2009-12-02 WO PCT/US2009/066451 patent/WO2010065668A1/en active Application Filing
- 2009-12-02 EP EP20090831071 patent/EP2373167A4/en not_active Withdrawn
- 2009-12-02 US US13/132,606 patent/US9120779B2/en not_active Expired - Fee Related
- 2009-12-02 NZ NZ593806A patent/NZ593806A/en not_active IP Right Cessation
- 2009-12-02 CN CN200980155930.1A patent/CN102300461B/zh not_active Expired - Fee Related
- 2009-12-02 AU AU2009322387A patent/AU2009322387A1/en not_active Abandoned
- 2009-12-02 MX MX2011005896A patent/MX2011005896A/es not_active Application Discontinuation
- 2009-12-02 WO PCT/US2009/066467 patent/WO2010065681A1/en active Application Filing
- 2009-12-02 NZ NZ593808A patent/NZ593808A/en not_active IP Right Cessation
- 2009-12-02 CN CN200980155944.3A patent/CN102300462B/zh not_active Expired - Fee Related
- 2009-12-02 SG SG2011039799A patent/SG171891A1/en unknown
- 2009-12-02 US US13/132,604 patent/US8865756B2/en not_active Expired - Fee Related
- 2009-12-02 SG SG2011039781A patent/SG171890A1/en unknown
- 2009-12-02 AU AU2009322400A patent/AU2009322400A1/en not_active Abandoned
- 2009-12-02 EP EP09831084A patent/EP2373168A4/en not_active Withdrawn
- 2009-12-02 JP JP2011539670A patent/JP2012510525A/ja active Pending
- 2009-12-02 EP EP13189259.8A patent/EP2774927A1/en not_active Withdrawn
- 2009-12-02 EA EA201190007A patent/EA201190007A1/ru unknown
- 2009-12-02 JP JP2011539662A patent/JP2012510523A/ja active Pending
- 2009-12-02 CA CA2745119A patent/CA2745119A1/en not_active Abandoned
- 2009-12-02 CA CA2750577A patent/CA2750577A1/en not_active Abandoned
- 2009-12-03 AR ARP090104677A patent/AR080264A1/es unknown
- 2009-12-03 TW TW98141406A patent/TWI472526B/zh not_active IP Right Cessation
- 2009-12-03 AR ARP090104678A patent/AR074474A1/es unknown
- 2009-12-03 TW TW098141404A patent/TWI494309B/zh not_active IP Right Cessation
-
2011
- 2011-05-31 IL IL213279A patent/IL213279A0/en unknown
- 2011-05-31 IL IL213278A patent/IL213278A0/en unknown
- 2011-06-02 CL CL2011001332A patent/CL2011001332A1/es unknown
- 2011-06-30 ZA ZA2011/04911A patent/ZA201104911B/en unknown
- 2011-07-01 CO CO11082846A patent/CO6390076A2/es not_active Application Discontinuation
-
2014
- 2014-10-20 US US14/518,940 patent/US20150038501A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR074474A1 (es) | Inhibidores ns5a de vhc | |
AR081831A1 (es) | Inhibidores de la proteina ns5a del virus de la hepatitis c (vhc) | |
AR084388A1 (es) | Compuestos nitrogenados heterociclicos inhibidores de la replicacion del vhc y composiciones farmaceuticas que los contienen | |
AR080263A1 (es) | Inhibidores ns5a de vhc | |
AR081848A1 (es) | Inhibidores de la proteina ns5a del vhc | |
AR076164A1 (es) | Inhibidores de anillos fusionados de hepatitis c | |
AR084720A1 (es) | Inhibidores de anillos fusionados triciclicos de hepatitis c | |
AR038703A1 (es) | Derivados de 5-feniltiazol y uso como inhibidor de quinasa p i 3 | |
AR068794A1 (es) | Compuestos antivirales | |
AR036492A1 (es) | Inhibidores de la 17beta-hidroxiesteroide deshidrogenasa tipo 3, composiciones farmaceuticas y el uso de dichos inhibidores para la elaboracion de un medicamento para el tratamiento de enfermedades androgeno dependientes | |
AR044519A1 (es) | Derivados de piridin-tiazol amina y de pirimidin-tiazol amina | |
CO6321229A2 (es) | Derivados de fenil benzamida utiles en el tratamiento de cancer y psoriasis | |
AR061840A1 (es) | Compuestos fosfinatos antivirales | |
AR060533A1 (es) | Compuestos fenil amido heterociclicos condensados | |
AR047981A1 (es) | Inhibidores de caspasa y sus usos correspondientes | |
CR8595A (es) | Inhibidor del dipeptidil-peptidasa | |
CO6180439A2 (es) | Derivados de quinuclidinol como antagonistas de receptores muscarinicos | |
AR073480A1 (es) | Benzamidas, su preparacion y su uso como medicamentos | |
AR083339A1 (es) | Compuestos de quinazolina como bloqueadores de los canales de sodio | |
AR043674A1 (es) | Derivados de piridazinona como inhibidores no nucleosidos de la transcriptasa reversa | |
AR073136A1 (es) | Compuestos de pirrol | |
AR049170A1 (es) | Derivados de pirimidina para el tratamiento del crecimiento celular anormal | |
CO4990929A1 (es) | Compuestos de difenilurea sustituidos con sulfonamidas como antagonistas de los receptores de il-8 | |
AR034422A1 (es) | Una composicion de resina de polipropileno que contiene un derivado de acido trimesico, un metodo para proveer una resina con un valor de niebla menor de 62%, un uso del derivado de acido trimesico como agente reductor de niebla, mezclas que contienen los derivados de acidos trimesicos, composicione | |
RU2011103454A (ru) | Бициклические гетероциклы в качестве ингибиторов киназы мек |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |